BioPharmSignal logoBioPharmSignal

Company Profile

Seres Therapeutics Stock Price, News & Analysis

Ticker:
MCRB
Exchange:
NASDAQ
Sector:
Biopharma
Location:
United States

Stock performance

4.85 USD (-2.32%)

Close

Last updated: July 27, 2026

71M USD

Market cap

Why the stock is moving

As of Jul 27, 2026, MCRB closed down 2.32% at $4.85. No new same-company headline was identified in the current news window.

Company overview

Business overview

Seres Therapeutics is a microbiome company that has worked to translate microbiome science into therapies for gastrointestinal and immune-related disease. Its journey has been shaped by high expectations and repeated resets.

Geographic Base and Sector Classification

Headquartered in the United States and listed on NASDAQ, Seres sits in specialty biotechnology.

Business Model Characteristics

The company depends on clinical validation, regulatory progress, and whether microbiome science can still produce durable value.

Position Within the Biotechnology Landscape

Seres is one of the more speculative microbiome names, with the stock heavily dependent on program credibility.

Future catalysts

Seres is still working its live biotherapeutic franchise, with SER-155 the clearest item to watch. The investigator-sponsored study in immune checkpoint-related enterocolitis gives the company a practical next readout while it keeps the broader inflammatory pipeline in view.

Recent news

The five most recent related feed items are shown below in reverse chronological order.

  1. 01

    Seres Therapeutics Announces Early Clinical Data Showing Potential for SER-155 in Immune Checkpoint Inhibitor-Related Enterocolitis (irEC), a Frequent Adverse Reaction That Forces Many Patients to Halt Cancer Treatment

    Source: Seres Therapeutics

  2. 02

    Seres Therapeutics to Host Webcast on July 8, 2026, to Discuss Results of Investigator-Sponsored Trial of Seres’ SER-155 in Immune Checkpoint Inhibitor-Related Enterocolitis

    Source: Seres Therapeutics

  3. 03

    Seres Therapeutics Announces Two Transactions to Strengthen Balance Sheet, Reduce On-Going Lease Costs and Extend Projected Operating Cash Runway Well Into the First Quarter of 2027

    Source: Seres Therapeutics

  4. 04

    Assembly Biosciences Announces Upcoming Investor Conference Presentations

    ASMB · Source: Assembly Biosciences

  5. 05

    Assembly Biosciences Announces the Closing of its Offering of Common Stock and Pre-Funded Warrants and Full Exercise of the Underwriters’ Option to Purchase Additional Shares

    ASMB · Source: Assembly Biosciences

Similar stocks

Peer names with similar commercial maturity, therapeutic overlap, or catalyst patterns.

ASMB

Assembly Biosciences

FNCH

Finch Therapeutics

Frequently Asked Questions

What is the current stock price of Seres Therapeutics (MCRB)?

Seres Therapeutics (MCRB) most recently closed at 4.85 USD, a -2.32% move versus the previous session.

What is the market cap of Seres Therapeutics (MCRB)?

Seres Therapeutics currently has a market capitalization of 71M USD on BioPharmSignal.

What does Seres Therapeutics do?

Seres Therapeutics is a microbiome company that has worked to translate microbiome science into therapies for gastrointestinal and immune-related disease. Its journey has been shaped by high expectations and repeated resets.

On which exchange is MCRB stock listed?

Seres Therapeutics (MCRB) is associated with NASDAQ, United States, Biopharma.

What is SER-155?

Seres is still working its live biotherapeutic franchise, with SER-155 the clearest item to watch.

Which conditions is Seres Therapeutics targeting with SER-155?

Seres is still working its live biotherapeutic franchise, with SER-155 the clearest item to watch.

How does Seres Therapeutics describe recent progress with SER-155?

Seres is still working its live biotherapeutic franchise, with SER-155 the clearest item to watch.

What is Seres?

Seres Therapeutics is a microbiome company that has worked to translate microbiome science into therapies for gastrointestinal and immune-related disease.